Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05157841 · ClinicalTrials.gov registry record · Phase 3
Phase 3, Sciatic Nerve Block With EXPAREL for Subjects Undergoing Bunionectomy
A Phase 3 study, sponsored by Pacira Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 185
- Enrollment target
NCT05157841 is a Phase 3 study that has completed, run by Pacira Pharmaceuticals. The registered enrollment target is 185 participants.
The verdict
NCT05157841, a Phase 3 study, has completed, sponsored by Pacira Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 185 participants
- Enrollment target
Study Summary
The study is conducted sequentially in two parts. Part A: The purpose is to obtain information on pharmacokinetic (PK) profile, pharmacodynamics (PD), efficacy, safety, and to assess the performance of 266 mg EXPAREL vs 133 mg EXPAREL. Part B: The purpose is to evaluate the efficacy and safety of the preferred dosage of EXPAREL from Part A compared with bupivacaine HCl.
Interventions
- DRUG Bupivacaine HCl
- DRUG Bupivacaine liposome injectable suspension 266 mg
- DRUG Bupivacaine liposome injectable suspension 133 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 185 participants |
| Start Date | 2022-02-15 |
| Est. Completion | 2022-08-17 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05157841
The ClinicalTrials.gov registry entry for NCT05157841 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 185 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pacira Pharmaceuticals, which has 88 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Bupivacaine HCl is the first listed.
NCT05157841 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05157841 about?
NCT05157841 is a clinical study titled "Phase 3, Sciatic Nerve Block With EXPAREL for Subjects Undergoing Bunionectomy". The study is conducted sequentially in two parts. Part A: The purpose is to obtain information on pharmacokinetic (PK) profile, pharmacodynamics (PD), efficacy, safety, and to assess the performance of 266 mg EXPAREL vs 133 mg EXPAREL. Part B: The purpose is to evaluate the efficacy and safety of ...
What is the current status of trial NCT05157841?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 185 participants. The study started on 2022-02-15. Estimated completion is 2022-08-17.
What interventions are being tested in trial NCT05157841?
The interventions under investigation include: Bupivacaine HCl (DRUG), Bupivacaine liposome injectable suspension 266 mg (DRUG), Bupivacaine liposome injectable suspension 133 mg (DRUG).
Who is sponsoring clinical trial NCT05157841?
This trial is sponsored by Pacira Pharmaceuticals, which has 88 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.